Menu Search
Investment Trusts

The Biotech Growth Trust PLC

BIOG:LSE

The Biotech Growth Trust PLC

Actions
  • Price (GBX)948.00
  • Today's Change26.00 / 2.82%
  • Shares traded68.64k
  • 1 Year change+25.90%
  • Beta0.5937
Data delayed at least 20 minutes, as of Nov 25 2024 16:35 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Total returns on £1000

1Y
Fund/benchmarkChange
PriceThe Biotech Growth Trust PLC (Ordinary Share)+22.41%
NAVThe Biotech Growth Trust PLC (Ordinary Share)--
Morningstar's BenchmarkNASDAQ Biotechnology TR GBP+19.66%
--
More ▼

Key statistics

On Monday, The Biotech Growth Trust PLC (BIOG:LSE) closed at 948.00, -11.27% below its 52-week high of 1,068.36, set on Oct 07, 2024.
52-week range
Today
736.30Nov 29 20231,068.36Oct 07 2024
Short selling activity
Low
Med
High
Provided by S&P Global Market Intelligence
Shares outstanding31.52m
Market cap290.61m GBP
Total assets344.57m GBP
Total expense ratio1.18%
High948.00
Low926.00
Previous close922.00
Average volume112.57k
YTD Change+6.04%
Beta0.5937
Diluted NAV (est)1,028.60
Diluted NAV (last pub)1,007.07
Premium/Discount-7.84%
Net Gearing+8.20%
Data delayed at least 20 minutes, as of Nov 25 2024 16:35 GMT.
More ▼

Annual Reports

Board of Directors

1/6

Roger Yates, Chairman

2/6

Geoff Hsu, Non-Executive Director

3/6

Lord Willetts, Independent Non-Executive Director

4/6

Julia Le Blan, Independent Non-Executive Director

5/6

Dr Nicola Shepherd, Independent Non-Executive Director

6/6

Hamish Baillie

Further Information

Contact

The Biotech Growth Trust PLC:
25 Southampton Buildings
London
WC2A 1AL

T: 0203 008 4910
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.